Dr.Reddy's Laboratories have announced the launch of Somazina, the innovator brand of Citicolin in India. Dr. Reddy's has partnered with Ferrer International S.A., Spain, the global innovator of Citicoline, to make Somazina available in India.
The drug is vital in the management of stroke and has been used for the treatment of post-stroke patients around the world.
Somazina is indicated to improve cognitive function in patients who have suffered from stroke or cerebral infarction, or who have undergone a brain surgery or have suffered from head injuries.
The brand, Citicoline is widely used as a neuro-protectant to help accelerate the recovery from stroke. It is used in both ischemic and haemorrhagic strokes, and provides a compelling option to physicians treating stroke patients.
"Citicoline is safe to use and may have a beneficial effect in stroke patients. Citicoline is the only drug, that in a number of different clinical stroke trials, has had some neuroprotective effect." shared Dr. Atul Prasad, Director & Sr. Consultant, BLK Super specialty hospital, Delhi.
Cerebral Stroke is the third leading cause of deaths in India, as per the Global Burden of Disease Study 2013. "Stroke is a major cause of disability and death in India. There is a pressing need for novel neuroprotective agents which can salvage brain tissue and optimize the functional outcome," said Subhash Kaul, renowned senior neurologist from NIMS, Hyderabad.